Application of Therapeutic Phages in Medicine by Sanjay Chhibber & Seema Kumari
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Application of Therapeutic Phages in Medicine 
Sanjay Chhibber* and Seema Kumari 
Department  of Microbiology, Basic Medical Sciences Building,  
Panjab University, Chandigarh, 
India 
1. Introduction 
For more than half a century, the doctors and clinicians have been relying primarily on 
antibiotics to treat infectious diseases caused by pathogenic bacteria. However, the 
emergence of bacterial resistance to antibiotics following widespread clinical, veterinary, 
and animal or agricultural usage has made antibiotics less and less effective (Fischetti, 2008; 
Perisien et al., 2008). These days scientists are now facing the threat of superbugs, i.e. 
pathogenic bacteria resistant to most or all available antibiotics (Livemore, 2004; Fischetti, 
2006). During the last 30 years, no new classes of antibiotics have been found, even with the 
help of modern biotechnology such as genetic engineering. Pharmaceutical companies have 
mainly focused on the development of new products derived from the known classes of 
antibiotics (Carlton, 1999; Sulakvelidze et al., 2001) which is a cause of major concern. Thus, 
exploring alternative approaches to develop antibacterial products is also a worthwhile task, 
and re-examining the potential of promising older methods might be of value. One of the 
possible replacements for antibiotics is the use of bacteriophages or simply phages as 
antimicrobial agents (Shasha et al., 2004; Vinodkumar et al., 2008). Phage therapy involves 
the use of lytic phages for the treatment of bacterial infections, especially those caused by 
antibiotic resistant bacteria. In general, there are two major types of phages, lytic and 
lysogenic. Only the lytic phages (also known as virulent phages) are a good choice for 
developing therapeutic phage preparations (Sandeep, 2006; Borysowski and Gorski, 2008). 
The bactericidal ability of phages has been used to treat human infections for years as a 
complement or alternative to antibiotic therapy (Alisky et al., 1998; Matsuzaki et al., 2005; 
Kysela & Turner, 2007). Bacteriophages, nature's tiniest viruses and it is estimated that there 
are about 1031 phages on earth making viruses the most abundant life form on earth 
(Ashelford et al., 2000; Hendrix, 2002; Dabrowska et al., 2005). Bacteriophages not only help 
in the treatments of bacterial infections in animals and human beings but also used in birds, 
fishes, plants, food material and biofilm eradication (Flaherty et al., 2000; Goode et al., 2003; 
Leverentz et al., 2003; Park & Nakai, 2003; Curtin & Donlan, 2006). 
2. Benefits of phage therapy over antibiotics 
Phages appear to be better therapeutic agents as they have several advantages over 
traditional antibiotics (Pirisi, 2000; Sulakvelidze et al., 2001; Matsuzaki et al., 2005). Majority 
of them are summarized in the Table given below. 
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Bacteriophages Antibiotics 
Phages are highly effective in killing their 
targeted bacteria i.e., their action is 
bactericidal 
Some antibiotics are bacteriostatic, i.e., they 
inhibit the growth of bacteria, rather than 
killing them (e.g., chloramphenicol). 
Production is simple and cheap. Production is complex and expensive. 
Phages are an ‘intelligent’ drug. They 
multiply at the site of the infection until 
there are no more bacteria. Then they are 
excreted.  
They are metabolized and eliminated from 
the body and do not necessarily concentrate 
at the site of infection. 
The pharmacokinetics of bacteriophage 
therapy is such that the initial dose 
increases exponentially if the susceptible 
bacterial host is available. In such cases, 
there is no need to administer the phages 
repeatedly. 
Repeated doses of antibiotic is required to 
cure the bacterial disease. 
The high selectivity/specificity of 
bacteriophages permits the targeting of 
specific pathogens, without affecting 
desirable bacterial flora which means that 
phages are unlikely to affect the 
“colonization pressure" of the patients 
Antibiotics demonstrate bactericidal or 
bacteriostatic effects not only on the cause of 
bacterial disease, but on all microorganisms 
present in the body including the host 
normal microflora.. Thus their non-selective 
action affects the patient's microbial balance, 
which may lead to various side effects. 
Because of phages specificity, their use is 
not likely to select for phage resistance in 
other (non-target) bacterial species 
The broad spectrum activity of antibiotics 
may select for resistant mutants of many 
pathogenic bacterial species. 
Humans are exposed to phages throughout 
life, and well tolerate them. No serious side 
effects have been described. 
Multiple side effects, including intestinal 
disorders, allergies, and secondary infections 
(e.g., yeast infections) have been reported.  
Phage-resistant bacteria remain susceptible 
to other phages having a similar host range.
Resistance to antibiotics is not limited to 
targeted bacteria. 
Phages are found throughout nature. This 
means that it is easy to find new phages 
when bacteria become resistant to them. 
Selecting a new phage (e.g., against phage-
resistant bacteria) is a rapid process and 
frequently can be accomplished in days.  
 Developing a new antibiotic (against 
antibiotic resistant bacteria) is a time 
consuming process and may take several 
years to accomplish. 
Phages may be considered as good 
alternative for patients allergic to 
antibiotics. 
If patient is allergic to antibiotic, treatment is 
very difficult 
Table 1. Comparison of phages and antibiotics regarding their prophylactic and therapeutic 
use. 
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There are also some disadvantages with the phage therapy approach. These include: 
 The problem which requires attention is the rapid clearance of phage by the spleen, 
liver and other filtering organs of reticuloendothelial system (Carlton, 1999). This can be 
taken care by doing serial passage in mice (Merril et al., 1996) so as to obtain a phage 
mutant capable of evading the reticuloendothelial system and therefore capable of long 
circulation in the blood. The minor variations in their coat proteins enable some 
variants to be less easily recognized by the RES organs, allowing them in the circulation 
for longer periods than the “average” wild-type phage.  
 This therapy can not be used for intracellular bacteria as the host is not available for 
interaction.  
 Theoretically development of neutralizing antibodies against phages could be an 
obstacle to the use phage therapy in recurrent infections. This needs to be confirmed 
experimentally. However, in the immunocompromised host where the immune system 
is depressed such as chronic infections, the phage therapy may work in this situation 
(Skurnik & Strauch, 2006). 
 The shelf life of phages varies and needs to be tested and monitored. 
 Phages are more difficult to administer than antibiotics. A physician needs special 
training in order to correctly prescribe and use phages. 
3. Safety of the therapeutic phage preparation 
During the long history of using phages as therapeutic agents through Eastern Europe and 
the former Soviet Union, there has been no report of serious complications associated with 
their use (Sulakvelidze & Morris, 2001). Phages are extremely common in environment and 
regularly consumed in foods (Bergh et al. 1989). In fact humans are exposed to phages from 
birth itself and therefore these constitute the normal microflora of the human body. They 
have been commonly found in human gastrointestinal tract, skin and mouth, where they are 
harboured in saliva and dental plaques (Bachrach et al., 2003). Phages are also abundant in 
environment including saltwater, freshwater, soil, plants and animals and they have been 
shown to be unintentional contents of some vaccines and sera commercially available in 
United States (Merril et al., 1972; Geier et al., 1975; Milch & Fornosi, 1975). Phages have high 
specificity for specific bacterial strains, a characteristic which requires careful targetting 
(Merril et al. 2003; Bradbury 2004). Therefore, phage therapy can be used to lyse specific 
pathogens without disturbing normal bacterial flora and phages pose no risk to anything 
other than their specific bacterial host (Lorch, 1999; Sulakvelidze et al., 2001; Duckworth & 
Gulig, 2002).  
 From a clinical standpoint, phage therapy appears to be very safe. Efficacy of natural 
phages against antibiotic-resistant Streptococci, Escherichia, Pseudomonas, Proteus, Salmonella, 
Shigella, Serratia, Klebsiella (Kumari et al., 2010), Enterobacter, Campylobacter, Yersinia, 
Acinetobacter and Brucella are being evaluated by researchers (Matsuzaki et al., 2005). 
However, in the last few years, modified phages are being explored increasingly, due to the 
limitations of phage therapy using lytic phages. The safety concerns regarding 
spontaneously propagating live microorganisms and the inconsistency of phage therapy 
results in the treatment of bacterial infections specifically induced scientists to explore more 
controllable phages (Skurnik et al., 2007). Phages can be modified to be an excellent 
therapeutic agent by directed mutation of the phage genome, recombination of phage 
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genomes, artificial selection of phages in vivo, chimeric phages and other rational designs 
which confer new properties on the phages. These new modified phages have been shown 
to successfully overcome challenges to earlier phage therapy (Moradpour & Ghasemian, 
2011). 
As with antibiotic therapy and other methods of countering bacterial infections, endotoxins 
(lipopolysaccharide) are released by the gram negative bacteria as a component of outer 
membrane. This can cause symptoms of fever, or in extreme cases, toxic shock (Herxheimer 
reaction) (Theil, 2004). To address the endotoxin release issue, recombinant phage derived 
from P. aeruginosa filamentous phage Pf3 was constructed by genetic modifications and the 
results showed that this filamentous phages could be used as effective anti-infection agent 
(Hagen & Blasi, 2003; Hagens et al. 2004). This phage had the benefit of minimizing the 
release of membrane associated endotoxins during phage therapy (Parisien et al., 2008). In 
order not to compromise on the issue of the safe use of therapeutic phage preparation, 
rigorous characterizations of each phage to be used therapeutically should be done, in 
particular, especially looking for potentially harmful genes in their genome (Payne & Jensen, 
2000; Carlton et al., 2005; Hanlon, 2007; Mattey & Spencer, 2008).  
4. Clinical application of bacteriophages 
4.1 Whole phage as antimicrobial agents 
4.1.1 Phage therapy in Humans 
However, although d’Hérelle carried out the first human therapeutic phage trial, the first 
article documenting phage therapy was on research conducted in Belgium by Bruynoghe 
and Maisin in 1921. They reported that phages when injected in six patients targeted 
staphylococcus near the base of cutaneous boils (furuncles and carbuncles), resulted in 
improvement within 48 hours and reduction in pain, swelling and fever. Merabishvili and 
workers (2009) used phage cocktail, consisting of exclusively lytic bacteriophages for the 
treatment of Pseudomonas aeruginosa and Staphylococcus aureus infections in burn wound 
patients in the Burn Centre of the Queen Astrid Military Hospital in Brussels, Belgium. The 
first controlled clinical trial of a therapeutic bacteriophage preparation (Biophage-PA) showed 
efficacy and safety in chronic otitis because of drug resistant P. aeruginosa in UCL Ear Institute 
and Royal National Throat, Nose and Ear Hospital, London, UK (Wright et al., 2009). Several 
clinical trials on phage therapy in humans were reported with the majority coming from 
researchers in Eastern Europe and the former Soviet Union (Abdul-Hassan et al., 1990; 
Sulakvelidze et al., 2001). One of the most extensive studies evaluating the application of 
therapeutic phages for prophylaxis of infectious diseases was conducted in Tbilisi, Georgia, 
during 1963 and 1964 and involved phages against bacterial dysentery (Babalova et al., 1968). 
The most detailed English language reports on phage therapy in humans were by Slopek 
and co workers who published a number of papers on the effectiveness of phages against 
infections caused by several bacterial pathogens, including multidrug-resistant mutants 
(Slopek et al., 1983, 1984, 1985; Kucharewicz-Krukowska et al., 1987; Weber-Dabrowska et 
al., 1987). Phages have been reported to be effective in treating various bacterial diseases 
such as cerebrospinal meningitis in a newborn (Stroj et al., 1999), skin infections caused by 
Pseudomonas, Staphylococcus, Klebsiella, Proteus, E. coli (Cislo et al., 1987), recurrent 
subphrenic and subhepatic abscesses (Kwarcinski et al., 1987), Staphylococcal lung infections 
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((Ioseliani et al., 1980; Kaczkowski et al., 1990), Pseudomonas aeruginosa infections in cystic 
fibrosis patients (Shabalova et al., 1995), eye infections (Proskurov, 1970), neonatal sepsis 
(Pavlenishvili & Tsertsvadze, 1993), urinary tract infections (Perepanova et al., 1995), and 
cancer (Weber-Dabrowska et al., 2001). Abdul-Hassan et al. (1990) reported on the treatment of 
30 cases of burn-wound associated antibiotic-resistant Pseudomonas aeruginosa sepsis. Bandages 
soaked with 1010 phages/ml were applied three times daily. Half of the cases were found to be 
improved. Markoishvili et al., (2002) reported the use of PhagoBioDerm, the phage 
impregnated polymer, to treat infected venous stasis skin ulcers. To patients that had failed to 
respond to other treatment approaches, PhagoBioDerm was applied to ulcers both alone and, 
where appropriate, in combination with other treatment strategies. Complete healing of ulcers 
was observed in 70% of the patients. Mushtaq et al., (2005) reported that a bacteriophage 
encoded enzyme, endosialidase E (endo E) selectively degrades the linear homopolymeric a-
2, 8-linked N acetylneuraminic acid capsule associated with the capacity of E. coli K1 strain 
to cause severe infection in the newborn infant. In one of the study, PhagoBioDerm (a 
wound-healing preparation consisting of a biodegradable polymer impregnated with 
ciprofloxacin and bacteriophages) was used in three Georgian lumberjacks from the village 
of Lia who were exposed to a strontium-90 source from two Soviet-era radiothermal 
generators they found near their village. In addition to systemic effects, two of them 
developed severe local radiation injuries which subsequently became infected with 
Staphylococcus aureus. Approximately 1 month after hospitalization, treatment with phage 
bioderm was initiated. Purulent drainage stopped within 2–7 days. Clinical improvement 
was associated with rapid (7 days) elimination of the S. aureus resistant to many antibiotics 
(including ciprofloxacin), but susceptible to the bacteriophages contained in the 
PhagoBioDerm preparation (Jikia et al., 2005). Leszczynski and co workers (2006) described 
the use of oral phage therapy for targeting Methicillin Resistant Staphylococcus aureus 
(MPSA) in a nurse who was a carrier. She had MRSA colonized in her gastrointestinal tract 
and also had a urinary tract infection. The result of phage therapy was complete elimination 
of culturable MRSA (Leszczynski et al., 2006).  
4.1.2 Animal trials 
In Britain, Smith and Huggins (1982, 1983) carried out a series of excellent, well-controlled 
studies on the use of phages in systemic E. coli infections in mice and then in diarrheic 
disease in young calves and pigs. Bogovazova et al., (1991) studied the effectiveness of 
specific phage therapy in non inbred white mice, caused by intraperitoneal injection of K. 
pneumoniae K25053 into the animals. Soothill, (1994) examined the ability of bacteriophage to 
prevent the rejection of skin grafts of experimentally infected guinea pigs. His findings 
demonstrated that the phage-treated grafts were protected in six of seven cases, while 
untreated grafts failed uniformly, suggesting that phage might be useful for the prevention 
of P. aeruginosa infections in patients with burn wounds. Phage therapy has been 
successfully used to remove E. coli 0157:H7 from livestock (Barrow et al., 1998; Kudva et al., 
1999; Tanji et al., 2004). One of the most successful studies was carried out by Biswas and 
coworkers (2002). These workers suggested that a single i.p. injection of 3 ×108 PFU of the 
phage strain, administered 45 minutes after the bacterial challenge (vancomycin-resistant 
Enterococcus faecium (VRE) was sufficient to rescue 100% of the animals. Even when 
treatment was delayed to the point where all animals were moribund, approximately 50% of 
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them were rescued by a single injection of the phage. The protective effect of bacteriophage 
was assessed against experimental S. aureus infection in mice. Subsequent intraperitoneal 
administration of purified ØMR11 (MOI of 0.1) suppressed S. aureus–induced lethality. This 
lifesaving effect coincided with the rapid appearance of ØMR11 in the circulation, which 
remained at substantial levels until the bacteria were eradicated (Matsuzaki et al. 2003). 
Benedict & Flamiano, (2004) evaluated the use of bacteriophages as therapy for Escherichia 
coli-induced bacteremia in mice. This experimental study showed clearly that a single dose 
of crude phage lysates administered by i.p. injection was enough to rescue bacteremic mice 
back to normal health after having been challenged with a lethal concentration of E. coli. 
Vinodkumar and co-workers (2005) studied the ability of bacterial viruses to rescue septicemic 
mice with multidrug resistant (MDR) Klebsiella pneumoniae isolated from neonatal 
septicemia. A single i.p. injection of 3x108 PFU of the phage strain administered 45 minutes 
after the bacterial challenge rescued 100% of the animals. Wills and colleagues (2005) also 
demonstrated the efficacy of bacteriophage therapy against S. aureus in a rabbit abscess model. 
2 x 109 PFU of staphylococcal phage prevented abscess formation in rabbits when it was 
injected simultaneously with S. aureus (8 x 107 CFU) into the same subcutaneous site. Phage 
multiplied in the tissues. The sewerage-derived bacteriophage reduced the abscess area and 
the count of S. aureus in the abscess was lowered in a bacteriophage dose dependent way 
(Will et al., 2005). Marza et al. (2006) reported the treatment of a dog with chronic bilateral 
otitis external that had consistently grown P. aeruginosa. This infection had failed to be 
resolved after repeated courses of topical and systemic antibiotics. After inoculation with 
400 PFU of bacteriophage into the auditory canal there was a marked improvement in the 
clinical signs, 27 hours after treatment. Wang et al., (2006) examined the effectiveness of 
phages in the treatment of imipenem resistant Pseudomonas aeruginosa (IMPR-Pa) infection in 
an experimental mouse model. A single i.p. inoculation of the phage strain ØA392 (MOI > 
0.01) at up to 60 min after the bacterial challenge was sufficient to rescue 100% of the 
animals. The workers demonstrated that the ability of the phage to rescue bacteremic 
animals was due to the functional capabilities of the phage and not to a non-specific 
immune effect. McVay and co-workers (2007) examined the efficacy of phage therapy in 
treating fatal Pseudomonas aeruginosa infections in mouse burn wound model. The results 
showed that a single dose of the Pseudomonas aeruginosa phage cocktail could significantly 
decrease the mortality of thermally injured, Pseudomonas aeruginosa-infected mice (from 6% 
survival without treatment to 22 to 87% survival with treatment) and that the route of 
administration was particularly important to the efficacy of the treatment, with the i.p. route 
providing the most significant (87%) protection. Watanabe et al. (2007) examined the 
efficacy of bacteriophage by using a gut-derived sepsis model caused by Pseudomonas 
aeruginosa in mice. Oral administration of a newly isolated lytic phage strain (KPP10) 
significantly protected mice against mortality with survival rates, 66.7% for the phage-
treated group as compared to 0% survival in saline treated control group. Mice treated with 
phage also had significantly lower numbers of viable Pseudomonas aeruginosa cells and lower 
level of inflammatory cytokines (tumor necrosis factor alpha TNF-α, interleukin-1ß [IL-1ß], 
and IL-6) in their blood and different organs such as liver and spleen.  
In recent years the phage therapy has received lot of attention due to an increase in the 
prevalence of antibiotic resistant strains in clinical settings. A numbers of recent 
experimental studies have proved the efficacy of phages in treating different infections. 
Chhibber & co workers (2008) had reported the therapeutic potential of phage SS in treating 
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Klebsiella pneumoniae induced respiratory infection in mice. A single intraperitoneal injection 
of (MOI of 200) phage (SS) administered immediately after i.n. challenge was sufficient to 
rescue 100% of animals from K. pneumoniae-mediated respiratory infections. The use of lytic 
bacteriophages to rescue septicemic mice with multidrug-resistant (MDR) Pseudomonas 
aeruginosa infection was evaluated (Vinodkumar et al., 2008). A single i.p. injection of 109 
PFU of the phage strain, administered 45 min after the bacterial challenge (107), was 
sufficient to rescue 100% of the animals. Malik & Chhibber (2009) investigated the protective 
effect of K. pneumoniae–specific bacteriophage KØ1 isolated from the environment in a 
mouse model of burn wound infection caused by K. pneumoniae. A substantial decrease in 
the bacterial load of blood, peritoneal lavage, and lung tissue was noted following treatment 
with the bacteriophage preparation. Recently in other studies, workers have successfully 
employed well characterized phages to treat burn wound infection induced by Klebsiella 
pneumoniae in mice. In this study, a single dose of phages, intraperitoneally (i.p.) at an MOI 
of 1.0, resulted in significant decrease in mortality, and this dose was found to be sufficient 
to completely cure K. pneumoniae infection in the burn wound model. Maximum decrease in 
bacterial counts in different organs was observed at 72 hours post infection (Kumari et al., 
2009). Kumari and co- workers (2010) evaluated the therapeutic potential of a well 
characterized phage Kpn5 in treating burn wound infection in mice as a single topical 
application of this phage was able to rescue mice from infection caused by K. pneumoniae 
B5055 in comparison to multiple applications of honey and Aloe vera gel (Kumari et al., 
2010). Recently, Kumari and co-workers (2011) evaluated the efficacy of silver nitrate and 
gentamicin in the treatment of burn wound infection and compared it with phage therapy 
using an isolated and well-characterized Klebsiella -specific phage, Kpn5. Phage Kpn5 mixed 
in hydrogel was applied topically at an MOI of 200 on the burn wound site. The efficacy of 
these antimicrobial agents was assessed on the basis of percentage survival of infected mice 
following treatment. The results showed that a single dose of phage Kpn5 resulted in a 
significant reduction in mortality (P<0.001) as compared to daily application of silver nitrate 
and gentamicin (Kumari et al., 2011). 
4.1.3 Phages in the eradication of biofilms 
Biofilms are densely packed communities of microorganisms growing on a range of biotic 
and abiotic surfaces and surround themselves with secreted extracellular polymer (EPS). 
Many bacterial species form biofilms and it is an important bacterial survival strategy. 
Biofilm formation is thought to begin when bacteria sense environmental conditions that 
trigger the transition to life on a surface. The structural and physiological complexity of 
biofilms has led to the idea that they are coordinated and cooperative groups, analogous to 
multicellular organisms (Passerini et al., 1992). In humans biofilms are responsible for many 
pathologies, most of them associated with the use of medical devices. A major problem of 
biofilms is their inherent tolerance to host defences and antibiotic therapies. Therefore there 
is an urgent need to develop alternative ways to prevent and control biofilm-associated 
clinical infections (Azeredo & Sutherland, 2008). Bacteriophages have been suggested as 
effective antibiofilm agents (Donlan, 2009). Use of indwelling catheters was often 
compromised as a result of biofilm formation. Curtin and Donlan (2006) investigated if 
hydrogel-coated catheters pretreated with coagulase negative bacteriophage would reduce 
Staphylococcus epidermidis biofilm formation. In our laboratory, efficacy of bacteriophage was 
assessed alone or in combination with amoxicillin, for the eradication of biofilm produced 
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by Klebsiella pneumoniae B5055 (Bedi et al., 2009). Similarly Verma et. al. (2009) also evaluated 
the efficacy of lytic bacteriophage KPO1K2 alone or in combination with another antibiotic, 
ciprofloxacin for eradicating the biofilm of Klebsiella pneumoniae in vitro (Verma et al., 2009). 
Despite the efficacy of antibiotics as well as bacteriophages in the treatment of bacterial 
infections, their role in treatment of biofilm associated infections is still under consideration 
especially in case of older biofilms. The ability of bacteriophage and their associated 
polysaccharide depolymerases was investigated to control enteric biofilm formation. The 
action of combined treatments of disinfectant and phage enzyme as a potentially effective 
biofilm control strategy was evaluated and the results showed that the combination of 
phage enzyme and disinfectant was found to be more effective than either of these when 
used alone (Tait et al., 2002). Since age of biofilm is a decisive factor in determining the 
outcome of antibiotic treatment, in one recent study, biofilm of K. pneumoniae was grown for 
extended periods and treated with ciprofloxacin and/or depolymerase producing lytic 
bacteriophage (KPO1K2). The reduction in bacterial numbers of older biofilm was greater 
after application of the two agents in combination as ciprofloxacin alone could not reduce 
bacterial biomass significantly in older biofilms (Verma et al., 2010).  
4.2 Phage products or phage lysins 
With the increasing worldwide prevalence of antibiotic resistant bacteria, bacteriophage 
endolysins represent a very promising novel alternative class of antibacterial in the fight 
against infectious disease. Pathogenic bacteria are increasingly becoming resistant to 
antibiotics. For nearly a century, scientists have attempted to treat bacterial infections with 
whole phages. Vincent Fischetti (1940) was the first, however, to focus on the deadly 
weapons, the potent and specific enzymes called lysins produced by these viruses. These 
lysins create lethal holes in bacterial cell walls. Fischetti has identified lysins that can kill a 
wide range of Gram-positive pathogenic bacteria, and have proven their effectiveness in 
both preventing and treating infections in mice, an important step towards their potential 
application in human disease (Fischetti, 2008). As an alternative to "classic" bacteriophage 
therapy, in which whole viable phage particles are used, one can also apply bacteriophage-
encoded lysis-inducing proteins, either as recombinant proteins or as lead structures for the 
development of novel antibiotics. Phage endolysins, or lysins, are enzymes that damage the 
cell walls' integrity by hydrolyzing the four major bonds in its peptidoglycan component 
(Loessner et al., 1997; Lopez et al., 2004). A number of studies have shown the enormous 
potential of the use of phage endolysins, rather than the intact phage, as potential 
therapeutics. The great majority of human infections such as viral or bacterial start at a 
mucous membrane site (upper and lower respiratory, intestinal, urogenital, and ocular) 
which are the reservoir for many pathogenic bacteria found in the environment (i.e., 
pneumococci, staphylococci, streptococci), many of which are reported to be resistant to 
antibiotics (Young, 1994). Therefore, various animal models of mucosal colonization were 
used to test the efficacy of phage lysins to kill organisms on these surfaces. An oral 
colonization model was developed for prevention and elimination of upper respiratory 
colonization of mice by group A streptococci by using a purified C1 phage lysin C1 (Nelson 
et al., 2001). Phage lytic enzymes have recently been proposed for the reduction of 
nasopharyngeal carriage of S. pneumoniae (Loeffler et al., 2001, 2003). In both these cases, 
when the animals were colonized with their respective bacteria and treated with a small 
amount of lysin specific for the colonizing organism, the animals were found to be free of 
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colonizing bacteria two to five hours after lysin treatment. Group B streptococci are the 
leading cause of neonatal meningitis and sepsis all over the world. A vaginal model for 
group B streptococci was established to remove colonization of the vagina and oropharynx 
of mice with a phage lysin (named PlyGBS). A single dose of PlyGBS significantly reduced 
bacterial colonization in both the vagina and oropharynx (Cheng et al., 2005). These results 
support the idea that such enzymes may be used in specific high-risk populations to control 
the reservoir of pathogenic bacteria and therefore control the disease. These phage enzymes 
are so efficient in killing pathogenic bacteria that they may be considered as valuable tools 
in controlling biowarfare bacteria. To determine the feasibility of this approach, Schuch and 
co workers (2002) identified a lytic enzyme PlyG from the gamma phage that is specific for 
Bacillus anthracis. This approach may be used in post-exposure cases of anthrax, in which 
individuals can be treated intravenously with PlyG to control the bacilli entering the blood 
after germination because higher doses of phage lysin or multiple doses will result in nearly 
100% protection. Recently, antimicrobial therapy of recombinant Cpl-1, a phage lysin 
specific for Streptococcus pneumoniae was reported to be effective in experimental 
pneumococcal meningitis using infant Wistar rats (Grandgirard et al., 2008).  
5. Phage application in food industry 
Food contamination is a serious issue because it results in foodborne diseases. Food 
contamination can be microbial or environmental, with the former being more common. 
Meat and poultry can become contaminated during slaughter through cross-contamination 
from intestinal fecal matter. Similarly, fresh fruits and vegetables can be contaminated if 
they are washed using water contaminated with animal manure or human sewage. During 
food processing, contamination is also possible from infected food handlers. Food 
contamination usually causes abdominal discomfort and pain, and diarrhea, but symptoms 
vary depending on the type of infection. At the present time, the leading causes of death due 
to foodborne bacterial pathogens are Listeria and Salmonella, followed closely by other 
foodborne pathogens such as Escherichia coli (E. coli O157:H7, in particular) and 
Campylobacter jejunii. Bacteriophages may provide a natural, non-toxic, safe, and effective 
means for significantly reducing or eliminating contamination of foods with specific 
pathogenic bacteria, thereby eliminating the risk, or significantly reducing the magnitude 
and severity, of foodborne illness caused by the consumption of foods contaminated with 
those bacteria (Meadet et al., 1999; Atturbury et al., 2003). The effectiveness of phage 
administration for the control of fish diseases and for food disinfection has also been 
documented. Nakai and co-workers (1999) and some other workers succeeded in saving the 
lives of cultured fish challenged by Lactococcus garvieae and Pseudomonas plecoglossicida, 
which are fish pathogens (Nakai et al., 1999; Nakai & Park, 2002; Park & Nakai, 2003). The 
need for control of pathogens during the manufacture of food is reflected by the incidence of 
foodborne bacterial infections. The use of phage or phage products in food production has 
recently become an option for the food industry as a novel method for biocontrol of 
unwanted pathogens, enhancing the safety of especially fresh and ready-to-eat food 
products (Hagens & Loessner, 2010). Phages were also shown to be effective for the 
elimination of food poisoning pathogens such as Listeria monocytogenes (Leverentz et al., 
2003), Campylobacter jejuni (Atterbury et al., 2003) and Salmonella spp. (Leverentz et al., 2001; 
Goode et al., 2003) from the surface of foods. The bacterial spot pathogen of tomato plants, 
Xanthomonas campestris pv. vesicatoria was successfully controlled with bacteriophage 
(Flaherty et al., 2000).  
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6. Phages as antibacterial nanomedicines 
Nowadays, apart from phage therapy, phages are also being used for phage display, DNA 
vaccine delivery, therapeutic gene delivery and bacterial typing Recently whole 
bacteriophage was constructed by fusing immunogenic peptides to modified coat proteins, 
which was found to be highly efficient DNA vaccine delivery vehicle (phage-display 
vaccination). Similarly the other approach has been incorporation of a eukaryotic promoter-
driven vaccine gene within the phage genome (phage DNA vaccination) (Clark & March, 
2006; Gao et al., 2010). Bacteriophages (phages) have been used for about two decades as 
tools for the discovery of specific target-binding proteins and peptides, and for almost a 
decade as tools for vaccine development. Drug-carrying phage represents a versatile 
therapeutic nanoparticle which because of tailoring of its coat can be equipped with a 
targeting moiety, and its massive drug-carrying capacity may become an important general 
targeting drug-delivery platform. In comparison to particulate drug-carrying devices, such 
as liposomes or virus-like particles, the arrangement of drug that is conjugated in high 
density on the external surface of the targeted particle is unique. A dense coating of the 
phage with aminoglycosides and other drugs might produce advantages that have been 
regarded as challenges in the application of phages as therapeutic agent. Most important 
issue in this field is the immunogenicity of bacteriophages on in vivo administration. This 
problem can be tackled as it has been shown that drug-carrying phages are hardly 
recognized by commercial antiphage antibodies and generate significantly lower antiphage 
antibody titers when used to vaccinate mice (in comparison to ‘naked' phages). Filamentous 
bacteriophages are the workhorse of antibody engineering and are gaining increasing 
importance in nanobiotechnology because of its nanometric dimentions (Yacoby et al., 2007). 
Vaks and Benhar (2011) described a new application in the area of antibacterial 
nanomedicines where antibody targeted, chloramphenicol drug loaded filamentous phage 
(M13) was used for inhibiting the growth of Staphylococcus aureus bacteria. Systemic 
administration of chemotherapeutic agents, in addition to its anti-tumor benefits, results in 
indiscriminate drug distribution and severe toxicity. Therefore to solve this problem, Bar 
and co workers (2008) used targeted anti-cancer therapy in the form of targeted drug-
carrying phage nanoparticles. The bacteriophages are also being currently evaluated for 
their biosensor potential. In a recent study it has been proposed to develop a unique and 
innovative biosensor based on induced luminescence of captured Biowarfare bacterial 
agents and organic light emitting diode (OLED) technology. The system would use array of 
bacteriophage engineered to express fluorescent protein in infected Biowarfare agents 
(Gooding, 2006). The specificity of the phage provides capture of only targets of interest, 
while the infection of the bacteria and natural replication of the expressed protein will 
provide the detection signal. Using novel OLED arrays, a phage array chip can be 
constructed similar to DNA chips for multianalyte detection.  
7. Conclusion 
Phage therapy for eliminating multidrug resistant bacteria is gaining importance. The 
abundance of phages in the environment makes it a relatively simple task to isolate phages 
against any given pathogen which can be characterized using a series of known protocols. 
The timescale and costs for the development of a new phage(s) for therapy will be a fraction 
of those for introducing a new antibiotic. Currently, many pathogenic bacteria have 
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acquired multiple drug resistance, which is a serious clinical problem. Phages, when 
properly selected, offer the most cost-effective alternative to antibiotics. These have proved 
to be efficient in bacterial elimination on single application and recently accepted for food 
treatment as well to counter food contamination during storage. Phages should be 
essentially free of contaminating bacterial toxin and also capable of evading the clearance by 
reticulendothelial system. Although some problems remain to be solved, many experts are 
of the opinion that phage therapy will find a niche in modern Western medicine in the 
future. Phage lytic enzymes have a broad application in the treatment of bacterial diseases. 
Whenever there is a need to kill bacteria, phage enzymes may be freely utilized. They may 
be used not only to control pathogenic bacteria on human mucous membranes, but may find 
application in the food industry to control disease causing bacteria. Phage lytic enzymes 
have yet to be exploited. Because of the serious problems of resistant bacteria in hospitals, 
day care centers, and nursing homes, particularly staphylococci and pneumococci, such 
enzymes may be of immediate benefit in these environments.  
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